New Jersey is currently home to 1652 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple Sclerosis
NCT06197685
Recruiting
The goal of this novel study is to compare the effect of a combined cognitive rehabilitation and exercise approach on new learning and memory (NLM) in persons with multiple sclerosis (pwMS) and mobility disability.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/03/2025
Locations: Kessler Foundation, East Hanover, New Jersey
Conditions: Multiple Sclerosis
Register for Updates
Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)
NCT06151197
Recruiting
This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Endo Site 62, Vineland, New Jersey
Conditions: Plantar Fibromatosis, Ledderhose Disease
Register for Updates
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
NCT05756777
Recruiting
The researchers are doing this study to see if the combination of gilteritinib with ivosidenib or enasidenib is a safe and effective treatment for people with relapsed/refractory AML with FLT3/IDH1 or FLT3/IDH2 gene mutations. The researchers will also look for the highest dose of the combination of gilteritinib with ivosidenib or enasidenib that causes few or mild side effects. When the highest safe dose is found, they will test that dose in new groups of participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
Conditions: Acute Myeloid Leukemia (AML)
Register for Updates
Sublingual Dexmedetomidine for Treating Opioid Withdrawal
NCT05712707
Recruiting
A major challenge to seeking treatment for opioid use disorder (OUD) is the withdrawal symptoms associated with cessation of opioid use. The signs and symptoms of opioid withdrawal include irritability, anxiety, muscular and abdominal pains, chills, nausea, diarrhea, yawning, runny eyes and nose, sweating, sneezing, weakness, and insomnia. The current gold standard of treatment involves a gradual reduction of the opioid drug dosage (tapering). However, as all opioids have potential for abuse and... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
03/03/2025
Locations: Clinilabs, Eatontown, New Jersey
Conditions: Opioid Use Disorder, Opioid Withdrawal
Register for Updates
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05259839
Recruiting
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: The Valley Hospital /ID# 243829, Paramus, New Jersey
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
NCT04991116
Recruiting
An open label phase 3 study
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Sunpharma site no 33, Voorhees, New Jersey
Conditions: Psoriatic Arthritis
Register for Updates
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-Onset Seizures
NCT04903314
Recruiting
The primary objective of this study is to assess the pharmacokinetics of cenobamate (YKP3089) in pediatric subjects with partial-onset (focal) seizures following single and multiple-dosing.
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
03/03/2025
Locations: Northeast Regional Epilepsy Group, Hackensack, New Jersey
Conditions: Partial Epilepsy
Register for Updates
Novel Imaging Technique to Assess Gynecologic Cancer
NCT04893434
Recruiting
This study will test a new type of DCE (dynamic contrast-enhanced) MRI (magnetic resonance imaging) to see whether, compared with traditional MRI, it produces better images that provide more information about tumors, which may help doctors make better decisions about treating women who have gynecologic cancer. MRI is commonly used to detect and evaluate many types of cancer, but its slow processing speed and the risk that images will be blurred if the patient moves inside the scanner can limit... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey
Conditions: Gynecologic Cancer
Register for Updates
Study of LAM561 Acid in Pediatric Patients with Malignant Glioma and Other Advanced Solid Tumors
NCT04299191
Recruiting
An open label, non-randomized study in pediatric patients with advanced high-grade gliomas and other solid tumors. The study will be performed in two phases: a dose escalation phase in up to 18 patients following a standard "3+3" design to establish dose-limiting toxicity (DLT) and a "safe" dose of LAM561 followed by an expanded safety cohort of up to 10 patients treated at the Maximum Tolerated Dose (MTD). If the MTD is well tolerated in the expanded safety cohort, that dose becomes the Recomm... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
03/03/2025
Locations: Hackensack Meridian Health, Inc, Edison, New Jersey
Conditions: High-grade Glioma, Solid Tumor, Unspecified, Child
Register for Updates
Dose Reduction of Postoperative Radiation for Soft Tissue Sarcoma of the Arms and Legs
NCT04288375
Recruiting
The investigators are doing this study to find out whether lowering the dose of postoperative radiation therapy and targeting a smaller area of tissue for treatment is as effective as the standard dose and volume of radiation therapy to control soft tissue sarcoma after surgery. They also want to find out whether the study approach causes fewer and less severe long-term side effects than the standard approach.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Memorial Sloan Kettering Basking Ridge (All protocol activities), Basking Ridge, New Jersey
Conditions: Soft Tissue Sarcoma
Register for Updates
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
NCT04165772
Recruiting
The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR solid tumors. The study will also look at the safety of the study drug.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Memorial Sloan Kettering Basking Ridge - Limited Protocol Activities, Basking Ridge, New Jersey
Conditions: Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-), Stage III (Any T, N+), Solid Tumor, Solid Tumor, Adult
Register for Updates
Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
NCT03442465
Recruiting
The purpose of this study is to look at the amount of function that returns in participants that have reconstruction with bone graft or artificial device and in participants who have tumor surgery plus regenerative osseous surgery. The study will look at the level of function for a period of 3 years after the surgery. Another purpose of this study is to look at how well the bone heals in participants undergoing regenerative surgery
Gender:
ALL
Ages:
4 years and above
Trial Updated:
03/03/2025
Locations: Memorial Sloan Kettering Monmouth (Consent and Followup), Middletown, New Jersey
Conditions: Bone Sarcoma, Osteosarcoma, Chondrosarcoma, Ewing's Sarcoma, Osseous Sarcoma, Bone Neoplasm
Register for Updates